Literature DB >> 24832874

Pooling prospective studies to investigate the etiology of second cancers.

Amanda Black1, Todd M Gibson1, Meredith S Shiels1, Yikyung Park1, Kim Robien2, Demetrius Albanes1, Stephanie J Weinstein1, Laura E Beane Freeman1, Gabriella Andreotti1, Mark P Purdue1, Joseph F Fraumeni1, Patricia Hartge1, Margaret A Tucker1, Robert N Hoover1, James R Cerhan3, Anne Zeleniuch-Jacquotte4, Rochelle E Curtis1, Joanne Elena5, Joshua N Sampson1, Amy Berrington de Gonzalez1, Lindsay M Morton6.   

Abstract

BACKGROUND: With over 13 million cancer survivors in the United States today, second cancers are of rapidly growing importance. However, data on nontreatment risk factors for second cancers are sparse. We explored the feasibility of pooling data from cohort studies of cancer incidence to investigate second cancer etiology.
METHODS: We combined data from five prospective studies including more than 800,000 individuals. We compared study designs and populations; evaluated availability of and ability to harmonize risk factor data; compared incidence and survival for common first primary malignancies and incidence of second primary malignancies; and estimated sample size requirements.
RESULTS: Overall, 96,513 incident, first primary malignancies were diagnosed during 1985 to 2009. Incidence rates and survival following the first primary varied among the cohorts, but most of the heterogeneity could be explained by characteristics of the study populations (age, sex, smoking, and screening rates). A total of 7,890 second primary cancers (excluding original primary site) were identified, yielding sufficient statistical power (≥80%) for detecting modest associations with risk of all second cancers among survivors of common first primary malignancies (e.g., colorectal cancer); however, there were insufficient events for studying survivors of rarer cancers or identifying risk factors for specific second cancers.
CONCLUSIONS: Pooling data from cohort studies to investigate nontreatment risk factors for second primary cancers seems feasible but there are important methodologic issues-some of which are barriers to specific research questions-that require special attention. IMPACT: Increased understanding of nontreatment risk factors for second cancers will provide valuable prevention and surveillance information. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24832874      PMCID: PMC4119533          DOI: 10.1158/1055-9965.EPI-14-0191

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  P F Pinsky; A Miller; B S Kramer; T Church; D Reding; P Prorok; E Gelmann; R E Schoen; S Buys; R B Hayes; C D Berg
Journal:  Am J Epidemiol       Date:  2007-01-22       Impact factor: 4.897

2.  Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study.

Authors:  A Schatzkin; A F Subar; F E Thompson; L C Harlan; J Tangrea; A R Hollenbeck; P E Hurwitz; L Coyle; N Schussler; D S Michaud; L S Freedman; C C Brown; D Midthune; V Kipnis
Journal:  Am J Epidemiol       Date:  2001-12-15       Impact factor: 4.897

3.  Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Authors:  Fadlo R Khuri; J Jack Lee; Scott M Lippman; Edward S Kim; Jay S Cooper; Steven E Benner; Rodger Winn; Thomas F Pajak; Brendell Williams; George Shenouda; Ian Hodson; Karen Fu; Dong M Shin; Everett E Vokes; Lei Feng; Helmuth Goepfert; Waun Ki Hong
Journal:  J Natl Cancer Inst       Date:  2006-04-05       Impact factor: 13.506

4.  Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.

Authors:  U Veronesi; L Mariani; A Decensi; F Formelli; T Camerini; R Miceli; M G Di Mauro; A Costa; E Marubini; M B Sporn; G De Palo
Journal:  Ann Oncol       Date:  2006-05-04       Impact factor: 32.976

5.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

Authors:  L B Travis; R E Curtis; B Glimelius; E J Holowaty; F E Van Leeuwen; C F Lynch; A Hagenbeek; M Stovall; P M Banks; J Adami
Journal:  J Natl Cancer Inst       Date:  1995-04-05       Impact factor: 13.506

6.  Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis.

Authors:  Houda Boukheris; Elaine Ron; Graça M Dores; Marilyn Stovall; Susan A Smith; Rochelle E Curtis
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

7.  The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group.

Authors: 
Journal:  Ann Epidemiol       Date:  1994-01       Impact factor: 3.797

8.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Authors:  Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Body fat distribution and 5-year risk of death in older women.

Authors:  A R Folsom; S A Kaye; T A Sellers; C P Hong; J R Cerhan; J D Potter; R J Prineas
Journal:  JAMA       Date:  1993-01-27       Impact factor: 56.272

10.  The Agricultural Health Study.

Authors:  M C Alavanja; D P Sandler; S B McMaster; S H Zahm; C J McDonnell; C F Lynch; M Pennybacker; N Rothman; M Dosemeci; A E Bond; A Blair
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

View more
  4 in total

1.  Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers.

Authors:  Meredith S Shiels; Todd Gibson; Joshua Sampson; Demetrius Albanes; Gabriella Andreotti; Laura Beane Freeman; Amy Berrington de Gonzalez; Neil Caporaso; Rochelle E Curtis; Joanne Elena; Neal D Freedman; Kim Robien; Amanda Black; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

Review 2.  The hallmarks of premalignant conditions: a molecular basis for cancer prevention.

Authors:  Bríd M Ryan; Jessica M Faupel-Badger
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

3.  Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

Authors:  Cecilia Bosco; Hans Garmo; Niklas Hammar; Göran Walldius; Ingmar Jungner; Håkan Malmström; Lars Holmberg; Mieke Van Hemelrijck
Journal:  BMC Cancer       Date:  2018-02-20       Impact factor: 4.430

4.  Persistent mRNA and miRNA expression changes in irradiated baboons.

Authors:  Matthias Port; Francis Hérodin; Marco Valente; Michel Drouet; Patrick Ostheim; Matthäus Majewski; Michael Abend
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.